SCHEMBL29907255

SCHEMBL29907255

Clc1ncc2ncccc2n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
RPS6KA5 O75582 5/20 0.46
RPS6KA4 O75676 1/20 0.46
NR4A2 P43354 2/20 0.44
MET P08581 1/20 0.41
PDK1 Q15118 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP3A4 P08684 1/20 0.41
CASP6 P55212 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
EGFR P00533 1/20 0.37
DOT1L Q8TEK3 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269742 1.00 ALDH1A1 (0.48) ALDH1A1RPS6KA5RPS6KA4NR4A2MET
SCHEMBL30523855 0.77 ALDH1A1 (0.52) ALDH1A1NR4A2TDP1CYP3A4KDM4E
SCHEMBL41713 0.74 ALDH1A1 (0.48) ALDH1A1METCYP3A4CASP6KDM4E
SCHEMBL3952706 0.74 ALDH1A1 (0.48) ALDH1A1NR4A2TDP1CYP3A4KDM4E
SCHEMBL31391337 0.74 ALDH1A1 (0.48) ALDH1A1CYP3A4KDM4EMAPTNPC1
SCHEMBL11024480 0.74 ALDH1A1 (0.48) ALDH1A1NR4A2TDP1CYP3A4KDM4E
SCHEMBL19044349 0.74 ALDH1A1 (0.48) ALDH1A1NR4A2METCYP3A4KDM4E
SCHEMBL31029246 0.74 ALDH1A1 (0.48) ALDH1A1RPS6KA5NR4A2TDP1CYP3A4
SCHEMBL15638042 0.74 ALDH1A1 (0.48) ALDH1A1RPS6KA5NR4A2TDP1CYP3A4
SCHEMBL30511326 0.74 ALDH1A1 (0.48) ALDH1A1CYP3A4KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-08-13 US disclosed
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-07-04 US disclosed
US-20240140945-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-05-02 US disclosed
EP-4326719-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-02-28 EP disclosed
CN-117177973-A Pyrido [3,2-D ] pyrimidine compounds and their use for the treatment of proliferative disorders 蒙特利尔大学 2023-12-05 CN disclosed
WO-2022221939-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS ALDH1A1 1636/4885RPS6KA5 442/4885RPS6KA4 406/4885
US-20240140945-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS ALDH1A1 1636/4885RPS6KA5 442/4885RPS6KA4 406/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS ALDH1A1 1636/4885RPS6KA5 442/4885RPS6KA4 406/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS ALDH1A1 1636/4885RPS6KA5 442/4885RPS6KA4 406/4885
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS ALDH1A1 1636/4885RPS6KA5 442/4885RPS6KA4 406/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD ALDH1A1 1619/4885RPS6KA5 441/4885RPS6KA4 406/4885
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, DPYD ALDH1A1 1619/4885RPS6KA5 441/4885RPS6KA4 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.